<code id='46B9F5C835'></code><style id='46B9F5C835'></style>
    • <acronym id='46B9F5C835'></acronym>
      <center id='46B9F5C835'><center id='46B9F5C835'><tfoot id='46B9F5C835'></tfoot></center><abbr id='46B9F5C835'><dir id='46B9F5C835'><tfoot id='46B9F5C835'></tfoot><noframes id='46B9F5C835'>

    • <optgroup id='46B9F5C835'><strike id='46B9F5C835'><sup id='46B9F5C835'></sup></strike><code id='46B9F5C835'></code></optgroup>
        1. <b id='46B9F5C835'><label id='46B9F5C835'><select id='46B9F5C835'><dt id='46B9F5C835'><span id='46B9F5C835'></span></dt></select></label></b><u id='46B9F5C835'></u>
          <i id='46B9F5C835'><strike id='46B9F5C835'><tt id='46B9F5C835'><pre id='46B9F5C835'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:entertainment    Page View:8735
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In